Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prestige Brands' Costs Grow With OTC Portfolio, But Retailer Orders Slow

Executive Summary

Consumer products firm's execs also expect "destocking" by drug, grocery and mass merchandise chains and other retail businesses to give way to increased purchase orders, but analysts say losing market share to e-commerce and higher freight costs could be here to stay.

You may also be interested in...



OTC Evolution For Prestige Brands Combines Near- And Long-Term Strategies

BC, Goody's, Monistat marketer boosts domestic and international OTC revenues immediately with C.B. Fleet acquisition, looks ahead to manufacturing expansion.

Safe Use Of Hydrogen-Peroxide Contact Lens Solution Magnified in US FDA Draft Guidance

Draft guidance pulls from Ophthalmic Devices Panel and Risk Communication Advisory Committee 2017 meeting to discuss more clearly communicating risks of the solutions to consumers while allowing products to remain available OTC.

House Members Object To Senate Adding Supplement MPL Proposal In FDA User Fee Bill

Members led by SC Republican Jeff Duncan and CA Democrat Tony Cárdenas, in letter to House speaker and minority leader, oppose MPL provision in latest version of S.4348 for re-authorizing FDA drug, biologic and medical device user fee programs.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS122452

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel